var data={"title":"Ibuprofen: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ibuprofen: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6351?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ibuprofen-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ibuprofen: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ibuprofen-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ibuprofen: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708913\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events (excluding NeoProfen):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal bleeding, ulcerations, and perforation (excluding NeoProfen):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI  bleeding are at greater risk for serious GI events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181456\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Addaprin [OTC];</li>\n      <li>Advil Junior Strength [OTC];</li>\n      <li>Advil Migraine [OTC];</li>\n      <li>Advil [OTC];</li>\n      <li>Caldolor;</li>\n      <li>Childrens Advil [OTC];</li>\n      <li>Childrens Motrin Jr Strength [OTC] [DSC];</li>\n      <li>Childrens Motrin [OTC];</li>\n      <li>Dyspel [OTC];</li>\n      <li>Genpril [OTC];</li>\n      <li>GoodSense Ibuprofen Childrens [OTC];</li>\n      <li>GoodSense Ibuprofen [OTC];</li>\n      <li>I-Prin [OTC];</li>\n      <li>IBU;</li>\n      <li>IBU-200 [OTC];</li>\n      <li>Ibuprofen Childrens [OTC];</li>\n      <li>Ibuprofen Comfort Pac;</li>\n      <li>Infants Advil [OTC];</li>\n      <li>KS Ibuprofen [OTC];</li>\n      <li>Motrin IB [OTC];</li>\n      <li>Motrin Infants Drops [OTC];</li>\n      <li>Motrin Junior Strength [OTC] [DSC];</li>\n      <li>Motrin [OTC] [DSC];</li>\n      <li>NeoProfen;</li>\n      <li>Provil [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181457\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advil;</li>\n      <li>Advil Pediatric Drops;</li>\n      <li>Caldolor;</li>\n      <li>Children&rsquo;s Advil;</li>\n      <li>Children&rsquo;s Europrofen;</li>\n      <li>Ibuprofen Muscle and Joint;</li>\n      <li>Motrin;</li>\n      <li>Motrin (Children's);</li>\n      <li>Motrin IB;</li>\n      <li>Pamprin Ibuprofen Formula;</li>\n      <li>Super Strength Motrin IB Liquid Gel Capsules</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181507\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181461\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesia (mild to moderate pain):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: 400 mg every 4 to 6 hours as needed; maximum: 3,200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">American Pain Society (off-label): 200 to 400 mg every 4 to 6 hours; maximum: 3,200 mg/day (APS 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations (off-label): 200 to 800 mg 3 to 4 times daily; usual dose: 400 mg; usual daily dose: 1,200 to 2,400 mg/day (Becker 2010; Blondell 2013; Derry 2009; Roelofs 2008); maximum: 3,200 mg/day (Blondell 2013; Derry 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (Caldolor): 400 to 800 mg every 6 hours as needed (maximum: 3,200 mg/day). <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antipyretic:</b> IV (Caldolor): <b>Note</b>: Patients should be well hydrated prior to administration. Initial: 400 mg, then every 4 to 6 hours or 100 to 200 mg every 4 hours as needed (maximum: 3,200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dysmenorrhea:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: 400 mg every 4 hours as needed; maximum: 3,200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations (off-label): 200 to 800 mg three to four times daily; usual daily dose: 1,200 to 2,400 mg/day; most sources did not exceed a daily dose of 2,400 mg/day and a maximum duration of 3 to 5 days (Majoribanks 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarthritis:</b> Oral: 400 to 800 mg 3 to 4 times daily (maximum: 3,200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Oral: 400 to 800 mg 3 to 4 times daily (maximum: 3,200 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>OTC labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Analgesic, antipyretic: Oral: 200 mg every 4 to 6 hours as needed; if no relief may increase to 400 mg every 4 to 6 hours as needed (maximum: 1,200 mg/day); Duration: treatment for &gt;10 days as an analgesic or &gt;3 days as an antipyretic is not recommended unless directed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Migraine: Oral: 400 mg at onset of symptoms (maximum: 400 mg/24 hours unless directed by health care provider)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pericarditis (off-label use):</b> Oral: <b>Note:</b> Administer in combination with colchicine therapy. Concurrent gastroduodenal prophylaxis with a proton pump inhibitor has been used and is recommended (ESC [Adler 2015]; Imazio 2013; Imazio 2005). With pericarditis postmyocardial infarction, the ACCF/AHA prefers the use of aspirin (ACCF/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute pericarditis:</i> 600 mg every 8 hours for 7 to 14 days followed by a gradual tapering of the dose by 200 to 400 mg every 1 to 2 weeks (ESC [Adler 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Recurrent pericarditis:</i> 600 mg every 8 hours (range: 1,200 to 2,400 mg) for weeks to months until complete symptom resolution followed by a gradual tapering of the dose by 200 to 400 mg every 1 to 2 weeks (ESC [Adler 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181483\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ibuprofen-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ibuprofen: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children &lt;12 years: 10 mg/kg (maximum dose: 400 mg) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/day or 2,400 mg/day, whichever is less.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed; maximum daily dose: 2,400 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Infants and Children &lt;50 kg: Limited data available in infants &lt;6 months: 4 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/day (American Pain Society 2016; Berde 1990; Berde 2002; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antipyretic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (Caldolor): <b>Note:</b> Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children &lt;12 years: 10 mg/kg (maximum dose: 400 mg) every 4 to 6 hours as needed; maximum daily dose: 40 mg/kg/day or 2,400 mg/day, whichever is less.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 12 to 17 years: 400 mg every 4 to 6 hours as needed (maximum daily dose: 2,400 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Infants &ge;6 months, Children, and Adolescents: 5 to 10 mg/kg/dose every 6 to 8 hours; maximum single dose: 400 mg; maximum daily dose: 40 mg/kg/day up to 1,200 mg, unless directed by physician (under physician supervision, not to exceed maximum of 2,400 mg daily) (Litalien 2001; Sullivan 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile idiopathic arthritis (JIA) (off-label use): </b> Oral: Children and Adolescents: 30 to 40 mg/kg/<b>day </b>in 3 to 4 divided doses; start at lower end of dosing range and titrate; patients with milder disease may be treated with 20 mg/kg/day; patients with more severe disease may require up to 50 mg/kg/day; maximum single dose: 800 mg; maximum daily dose: 2,400 mg (Giannini 1990; Kliegman 2011; Litalien 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Patent ductus arteriosus:</b> IV (ibuprofen lysine [NeoProfen]): Infants weighing between 500 to 1,500 g and &le;32 weeks' GA: Initial dose: Ibuprofen 10 mg/kg, followed by two doses of 5 mg/kg at 24 and 48 hours. Dose should be based on birth weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>OTC labeling (analgesic, antipyretic):</b> Oral: <b>Note:</b> Discontinue use and consult health care provider if no improvement within 24 hours after initiating therapy or if symptoms persist &gt;3 days or worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants and Children 6 months to 11 years:</i> See table; use of weight to select dose is preferred; doses may be repeated every 6 to 8 hours (maximum: 4 doses/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &ge;12 years and Adolescents:</i> Refer to adult dosing.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Ibuprofen Dosing (Infants and Children 6 months to 11 years)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Weight (Preferred)<sup class=\"footnote-number\">a</sup></p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">kg</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">lb</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>a</sup>Manufacturer's recommendations are based on weight in pounds (OTC labeling); weight in kg listed here is derived from pounds and rounded; kg weight listed also is adjusted to allow for continuous weight ranges in kg.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.4 to 8.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 17</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 11 mo</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.2 to 10.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18 to 23</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 23 mo</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.9 to 16.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16.4 to 21.7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36 to 47</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 5 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21.8 to 27.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">48 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 8 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">27.3 to 32.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 71</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 to 10 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">32.7 to 43.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">72 to 95</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181462\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; consider reduced initial dosage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6784600\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution; avoid use in advanced renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">KDIGO 2012 guidelines provide the following recommendations for NSAIDs:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Avoid use in patients with intercurrent disease that increases risk of acute kidney injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neoprofen: If anuria or marked oliguria (urinary output &lt;0.6 mL/kg/hour) evident at the scheduled time of the second or third dose, hold dose until renal function returns to normal. Use is contraindicated in preterm infants with significant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181463\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use caution and discontinue if hepatic function worsens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Migraine: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">KS Ibuprofen: 200 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Comfort Pac: 800 mg [contains methylparaben, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caldolor: 400 mg/4 mL (4 mL [DSC]); 800 mg/8 mL (8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as lysine [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NeoProfen: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [contains edetate disodium, fd&amp;c red #40, polysorbate 80, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), edetate disodium, fd&amp;c red #40, polysorbate 80, propylene glycol, sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), propylene glycol, sodium benzoate; blue raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (30 mL, 120 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Advil: 100 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (60 mL [DSC]) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 100 mg/5 mL (120 mL [DSC]) [alcohol free, dye free; contains sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen Childrens: 100 mg/5 mL (120 mL) [alcohol free, dye free, gluten free; contains polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Childrens: 100 mg/5 mL (118 mL) [alcohol free; contains corn starch, fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen Childrens: 100 mg/5 mL (118 mL) [alcohol free; contains corn starch, fd&amp;c red #40, polysorbate 80, sodium benzoate; bubble-gum flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants Advil: 50 mg/1.25 mL (30 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants Advil: 50 mg/1.25 mL (15 mL) [alcohol free, dye free; contains edetate disodium, polysorbate 80, propylene glycol, sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin: 40 mg/mL (15 mL [DSC]) [alcohol free, dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL [DSC]) [contains fd&amp;c red #40, polysorbate 80, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [contains fd&amp;c red #40, polysorbate 80, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL) [alcohol free; contains fd&amp;c red #40, polysorbate 80, sodium benzoate, sorbitol; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Infants Drops: 50 mg/1.25 mL (15 mL [DSC], 30 mL) [alcohol free, dye free; contains polysorbate 80, sodium benzoate, sorbitol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (5 mL, 118 mL, 120 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Addaprin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil: 200 mg [contains methylparaben, propylparaben, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Junior Strength: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dyspel: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genpril: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Ibuprofen: 200 mg [gluten free; contains corn starch, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">I-Prin: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IBU-200: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IBU: 400 mg, 600 mg, 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg [contains corn starch, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin IB: 200 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg, 400 mg, 600 mg, 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advil Junior Strength: 100 mg [scored; contains aspartame, fd&amp;c blue #2 aluminum lake; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin: 50 mg [DSC] [contains aspartame, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Childrens Motrin Jr Strength: 100 mg [DSC] [contains aspartame, brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC] [contains aspartame, brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Motrin Junior Strength: 100 mg [DSC] [contains aspartame, fd&amp;c yellow #6 (sunset yellow)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181416\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884416\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">EnovaRX-Ibuprofen cream is compounded from a kit. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874617\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=8547\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181435\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food or milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caldolor: For IV administration only; infuse over at least 30 minutes (adults) or 10 minutes (pediatric).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NeoProfen (ibuprofen lysine): For IV administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed, interrupt TPN for 15 minutes prior to and after ibuprofen administration, keeping line open with dextrose or saline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181434\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Inflammatory diseases and rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, osteoarthritis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ibuprofen injection (Caldolor): Management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics in adults and children 6 months and older; reduction of fever in adults and children 6 months and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ibuprofen lysine injection (NeoProfen): Patent ductus arteriosus (PDA): To close a clinically significant PDA in premature infants weighing between 500-1500 g who are no more than 32 weeks of gestational age when usual medical management (eg, diuretics, fluid restriction, respiratory support) is ineffective.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">OTC labeling: Reduction of fever; management of pain due to headache, sore throat, arthritis, physical or athletic overexertion (eg, sprains/strains), menstrual pain, dental pain, minor muscle/bone/joint pain, backache, pain due to the common cold and flu</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474800\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Pericarditis; Acute migraine headache; Ankylosing spondylitis; Cystic fibrosis; Gout; Juvenile idiopathic arthritis; Migraine prophylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181516\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-left:2em;\">Haltran may be confused with Halfprin</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Motrin may be confused with Neurontin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Ibuprofen is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). May increase risk of acute kidney injury and further decline of kidney function in elderly patients with stages IV or higher chronic kidney disease or CrCl less than 30 mL/minute (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Injectable formulations: Both ibuprofen and ibuprofen lysine are available for parenteral use. Ibuprofen lysine is <b>only</b> indicated for closure of a clinically-significant patent ductus arteriosus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181423\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Edema (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness (3% to 9%), headache (1% to 3%), nervousness (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash (3% to 9%), pruritus (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Fluid retention (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Epigastric pain (3% to 9%), heartburn (3% to 9%), nausea (3% to 9%), abdominal pain (1% to 3%), constipation (1% to 3%), decreased appetite (1% to 3%), diarrhea (1% to 3%), dyspepsia (1% to 3%), flatulence (1% to 3%), vomiting (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Otic: Tinnitus (3% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, acute renal failure, agranulocytosis, allergic rhinitis, alopecia, amblyopia, anaphylaxis, aplastic anemia, aseptic meningitis, azotemia, blurred vision, bone marrow depression, bronchospasm, cardiac arrhythmia, cardiac failure, confusion, conjunctivitis, cystitis, decreased creatinine clearance, decreased hematocrit, decreased hemoglobin, decreased platelet aggregation, depression, drowsiness, dry eye syndrome, duodenal ulcer, emotional lability, eosinophilia, epistaxis, erythema multiforme, gastric ulcer, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, hallucination, hearing loss, hematuria, hemolytic anemia, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypertension, insomnia, jaundice, leukopenia, melena, neutropenia, palpitations, pancreatitis, peripheral neuropathy, polydipsia, polyuria, skin photosensitivity, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis, vision changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection: Ibuprofen (Caldolor):</b> Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema, hypertension (10%; including exacerbation), myocardial infarction, peripheral edema (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (12%), dizziness (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Exfoliative dermatitis, pruritus, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (4% to 19%), hypoalbuminemia (10%), hypernatremia (7% to 10%), changes in LDH (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: vomiting (22%), flatulence (16%), diarrhea (10%), dyspepsia (1% to 4%), abdominal discomfort (&le;3%), abdominal pain, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (5%), renal toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (4% to 36%), eosinophilia (26%), hypoproteinemia (10% to 13%), neutropenia (13%), hemorrhage (10%), thrombocythemia (3% to 10%), wound hemorrhage (3%), decreased hemoglobin (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&le;15%), increased serum AST ( &le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (7% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bacterial pneumonia (3% to 10%), cough (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection: Ibuprofen lysine (NeoProfen):</b> Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (7% to 10%), edema (4%), cardiac failure, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intraventricular hemorrhage (29%), convulsions, eating disorder, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin irritation (16%), skin lesion (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (12%), hypoglycemia (12%), adrenocortical insufficiency (7%), hypernatremia (7%), hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Enterocolitis (22%), gastrointestinal disease (non NEC; 22%), abdominal distension, cholestasis, gastritis, gastroesophageal reflux disease, inguinal hernia, intestinal obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (9%), uremia (7%), decreased urine output (3%; small decrease reported on days 2 to 6 with compensatory increase in output on day 9)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (32%), neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (43%), infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (7%), renal insufficiency (6%), increased serum creatinine (3%), renal failure (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea (28%), respiratory tract infection (19%), respiratory failure (10%), atelectasis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Reduced intake of food/fluids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Gastrointestinal perforation, hepatotoxicity (idiosyncratic) (Chalasani 2014), necrotizing enterocolitis, pulmonary hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181438\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ibuprofen (eg, anaphylactic reactions, serious skin reactions) or any component of the formulation; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg, bronchial asthma, aspirin intolerance, rhinitis); use in the setting of coronary artery bypass graft (CABG) surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen lysine (NeoProfen): Preterm neonates: With proven or suspected infection that is untreated; congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow (eg, pulmonary atresia, severe coarctation of the aorta, severe tetralogy of Fallot); bleeding (especially those with active intracranial hemorrhage or GI bleeding); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis; or significant renal function impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Cerebrovascular bleeding or other bleeding disorders; active gastric/duodenal/peptic ulcer, active GI bleeding; inflammatory bowel disease; uncontrolled heart failure; moderate [IV formulation only] to severe renal impairment (creatinine clearance [CrCl] &lt;30 mL/minute); deteriorating renal disease; moderate [IV formulation only] to severe hepatic impairment; active hepatic disease; hyperkalemia; third trimester of pregnancy; breast-feeding; patients &lt;18 years of age [IV formulation only]; patients &lt;12 years of age [oral formulation only]; systemic lupus erythematosus [oral formulation only]; children suffering from dehydration as a result of acute diarrhea, vomiting, or lack of fluid intake</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">OTC labeling: When used for self-medication, do not use if previous allergic reaction to any other pain reliever/fever reducer; prior to or following cardiac surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181420\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events:<b> [US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including fatal MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of cardiovascular events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors. New-onset hypertension or exacerbation of hypertension may occur (NSAIDS may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention; use with caution in patients with edema. Avoid use in heart failure (ACCF/AHA [Yancy 2013]). Avoid use in patients with a recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious gastrointestinal inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, fulminant hepatitis, liver necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic events: Blurred/diminished vision, scotomata, and changes in color vision have been reported. Discontinue therapy and refer for ophthalmologic evaluation if symptoms occur. Periodically evaluate vision in all patients receiving long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with advanced renal disease; discontinue use with persistent or worsening abnormal renal function tests. Use of ibuprofen lysine (NeoProfen) is contraindicated in preterm infants with significant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are at greater risk for serious GI events; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ibuprofen injection (Caldolor): Must be diluted prior to administration; hemolysis can occur if not diluted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ibuprofen lysine injection (NeoProfen): Hold second or third doses if urinary output is &lt;0.6 mL/kg/hour. May alter signs of infection. May inhibit platelet aggregation; monitor for signs of bleeding. May displace bilirubin; use caution when total bilirubin is elevated. Long-term evaluations of neurodevelopment, growth, or diseases associated with prematurity following treatment have not been conducted. A second course of treatment, alternative pharmacologic therapy or surgery may be needed if the ductus arteriosus fails to close or reopens following the initial course of therapy. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self medication (OTC use): Prior to self-medication, patients should contact health care provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, or are &ge;60 years of age. If patients are using for migraines, they should also contact health care provider if they have not had a migraine diagnosis by health care provider, a headache that is different from usual migraine, worst headache of life, fever and neck stiffness, headache from head injury or coughing, first headache at &ge;50 years of age, daily headache, or migraine requiring bed rest. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Stop use and consult a health care provider if symptoms do not improve within first 24 hours of use (children) get worse, or newly appear, fever lasts for &gt;3 days or pain lasts &gt;3 days (children) and &gt;10 days (adults). Do not give for &gt;10 days unless instructed by healthcare provider. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181500\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181425\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8547&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs).  Avoid the use of diclofenac/misoprostol with other NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PEMEtrexed: Ibuprofen may increase the serum concentration of PEMEtrexed.  Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181452\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ibuprofen peak serum levels may be decreased if taken with food. Management: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7684272\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because NSAIDs cause premature closure of the ductus arteriosus, prescribing information for ibuprofen specifically states use should be avoided starting at 30-weeks gestation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of NSAIDs can be considered for the treatment of mild rheumatoid arthritis flares in pregnant women; however, use should be minimized or avoided early and late in pregnancy (Bermas 2014; Saavedra Salinas 2015). If treatment of migraine is needed in pregnant women, ibuprofen is preferred when an NSAID is required; however, other agents are recommended as initial therapy (Amundsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181441\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ibuprofen is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of ibuprofen is 0.6% to 0.9% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 10 to 15 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25%, breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest milk concentration (0.59 mcg/mL), the estimated daily infant dose via breast milk is 0.089 mg/kg/day. This milk concentration was obtained following maternal administration of oral ibuprofen &ge;600 mg/day (Rigourd 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Based on the available data, adverse events have not been reported in breastfeeding infants and milk production is not affected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, NSAIDs may be used in postpartum women who wish to breastfeed and if needed for postpartum pain, ibuprofen is the preferred agent (Montgomery 2012). Ibuprofen is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002). Use should be avoided in women breastfeeding infants with platelet dysfunction or thrombocytopenia (Bloor 2013; Sammaritano 2014). The manufacturer recommends that the decision to breastfeed during therapy consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181442\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine and/or potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181428\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, chemistry profile, occult blood loss and periodic liver function tests; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (urine output, serum BUN and creatinine); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation; blood pressure; periodic ophthalmic exams with long-term therapy; signs of infection (ibuprofen lysine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181431\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Plasma concentrations &gt;200 mcg/mL may be associated with severe toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181419\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181437\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: Analgesic: Within 30 to 60 minutes (Davies 1998; Mehlisch 2013); Antipyretic: Single oral dose 8 mg/kg (Kauffman 1992): Infants &le;1 year: 69 &plusmn; 22 minutes; Children &ge;6 years: Single oral dose 8 mg/kg (Kauffman 1992): 109 &plusmn; 64 minutes; Adults: &lt;1 hour (Sullivan 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Antipyretic: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: Antipyretic: 6 to 8 hours (Sullivan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid (85%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Febrile children &lt;11 years: 0.2 L/kg; Adults: 0.12 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Ibuprofen (Caldolor):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients 6 months to &lt;2 years: 0.31 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients 2 to 16 years: 0.23 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Ibuprofen lysine: Premature neonates, GA &lt;32 weeks: Variable results observed: 0.32 L/kg, others have reported: a central compartment Vd that decreases with increasing PNA and ductal closure (Van Overmeire, 2001) and a  V<sub>d</sub>, apparent: 0.062 L/kg in 21 premature neonates (GA &lt;32 weeks, PNA: &lt;1 day) (Aranda 1997); a 2-compartment open model was observed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%; Premature infants: ~95% (Aranda 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via oxidation; <b>Note:</b> Ibuprofen is a racemic mixture of R and S isomers; the R isomer (thought to be inactive) is slowly and incompletely (~60%) converted to the S isomer (active) in adults; the amount of conversion in children is not known, but it is thought to be similar to adults; a study in preterm neonates estimated the conversion to be 61% after prophylactic ibuprofen use and 86% after curative treatment (Gregoire 2004).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen (Caldor): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients: 6 months to &lt;2 years: 1.8 hours; 2 to 16 years: ~1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 2.22 to 2.44 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ibuprofen lysine (Neoprofen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Premature neonates, GA &lt;32 weeks: Reported data highly variable</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">R-enantiomer: 10 hours; S-enantiomer: 25.5 hours (Gregoire 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Age-based observations:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA &lt;1 day: 30.5 &plusmn; 4.2 hours (Aranda 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA 3 days: 43.1 &plusmn; 26.1 hours (Van Overmeire 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">PNA 5 days: 26.8 &plusmn; 23.6 hours (Van Overmeire 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 months to 10 years: Oral suspension: 1.6 &plusmn; 0.7 hours (Kauffman 1992) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~2 hours; End-stage renal disease: Unchanged (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Tablets: 1 to 2 hours; Suspension: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with cystic fibrosis (Scott 1999): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Suspension (n=22): 0.74 &plusmn; 0.43 hours (median: 30 minutes) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chewable tablet (n=4): 1.5 &plusmn; 0.58 hours (median: 1.5 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet (n=12): 1.33 &plusmn; 0.95 hours (median: 1 hour) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as metabolites (45% to 80%); ~1% as unchanged drug and 14% as conjugated); some feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181440\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Advil Migraine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (40): $6.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (2): $0.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (80): $6.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Advil Junior Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (24): $4.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Ibuprofen Comfort Pac Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (1): $74.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Caldolor Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg/8 mL (8 mL): $19.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ibuprofen Lysine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $487.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NeoProfen Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (2 mL): $732.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Childrens Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (120 mL): $5.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Childrens Motrin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (120 mL): $6.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $0.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Infants Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/1.25 mL (15 mL): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Motrin Infants Drops Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/1.25 mL (15 mL): $5.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Advil Junior Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (24): $4.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Advil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (200): $16.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (IBU Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $20.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (90): $26.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (90): $34.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ibuprofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $5.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (500): $170.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $51.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $80.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Motrin IB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (50): $5.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Provil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (50): $3.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181443\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actiprofen (IE);</li>\n      <li>Actron (CR, DO, GT, HN, NI, PA, PY, SV, UY);</li>\n      <li>Adex 200 (IL);</li>\n      <li>Adex Liqui-Gels (IL);</li>\n      <li>Advel (BD);</li>\n      <li>Advil (AU, BR, CO, EE, FR, HK, HU, IE, IL, LB, MX, PH, PL, RO, SA, VE, VN, ZA);</li>\n      <li>Afebril (EC, PY);</li>\n      <li>Aktren (AT);</li>\n      <li>Algofen (IT);</li>\n      <li>Am-Fam 400 (IN);</li>\n      <li>Anafen (ID);</li>\n      <li>Anco (DE);</li>\n      <li>Antarene (FR);</li>\n      <li>Arfen (ID);</li>\n      <li>Argifen (ES);</li>\n      <li>Asfen-400 (ET);</li>\n      <li>Balkaprofen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Bebyzal (KR);</li>\n      <li>Bestafen (MX);</li>\n      <li>Bifen (HK, SG);</li>\n      <li>Bofen (UA);</li>\n      <li>Brufen (AE, AT, AU, BD, BE, BH, CH, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IQ, IR, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, LY, MT, NL, NO, NZ, OM, PH, PK, PT, QA, RO, RU, SA, SE, SG, SI, SK, SY, TR, TW, VN, YE, ZA, ZW);</li>\n      <li>Brufen 400 (IL);</li>\n      <li>Brufen Forte (ID);</li>\n      <li>Brufen Retard (SG);</li>\n      <li>Brufen Syrup for Children (KR);</li>\n      <li>Brufort (IT);</li>\n      <li>Brupro (IE);</li>\n      <li>Bufect (ID, LK);</li>\n      <li>Bufect Forte (ID);</li>\n      <li>Buplex (IE);</li>\n      <li>Buprex (EC);</li>\n      <li>Burana (FI);</li>\n      <li>Butafen (ET);</li>\n      <li>Carol (KR);</li>\n      <li>Cefen (TH);</li>\n      <li>Cuprofen (TH);</li>\n      <li>Dafen-Q (KR);</li>\n      <li>Dalsy (ES);</li>\n      <li>Degiton (TW);</li>\n      <li>Diffutab SR 600 (KR);</li>\n      <li>Dolafen (PH);</li>\n      <li>Dolan FP (PH);</li>\n      <li>Dolex (ZW);</li>\n      <li>Dolgit (AE, BH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dolocyl (CH);</li>\n      <li>Dolomax (PE);</li>\n      <li>Doloral (PE);</li>\n      <li>Dolormin (DE);</li>\n      <li>Dolprin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Drin (GR);</li>\n      <li>Druisel (AR);</li>\n      <li>Easofen (MT);</li>\n      <li>Evofen (MY);</li>\n      <li>Expanfen (FR);</li>\n      <li>Extrapan Gel (HK);</li>\n      <li>Farsifen Forte (ID);</li>\n      <li>Febratic (MX);</li>\n      <li>Fenatic (ID);</li>\n      <li>Fenbid (AE, BF, BH, BJ, CI, CN, CY, EG, ET, GB, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Fenpaed (NZ);</li>\n      <li>Fever-Free (PH);</li>\n      <li>Flamex (BD);</li>\n      <li>Focus (IT);</li>\n      <li>Genofen (ET);</li>\n      <li>Gofen (LK, PH, TZ);</li>\n      <li>Gyno-neuralgin (DE);</li>\n      <li>Hagifen (VN);</li>\n      <li>Ibufac (MY);</li>\n      <li>Ibufen (IL, KR);</li>\n      <li>Ibuflam (MX);</li>\n      <li>Ibufug (DE);</li>\n      <li>Ibugesic (IN, LB, LK);</li>\n      <li>Ibulgan (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ibumetin (AT, DK, FI, NL, NO, SE);</li>\n      <li>Ibunorm (UA);</li>\n      <li>Ibupirac (AR, CL);</li>\n      <li>Ibuprofen (HK);</li>\n      <li>Ibusal (FI);</li>\n      <li>Ibuspan (ZW);</li>\n      <li>Imet (UA);</li>\n      <li>Infacalm (HK);</li>\n      <li>Inufen (ET);</li>\n      <li>Ipren (DK, RU, SE);</li>\n      <li>Iprox (ID);</li>\n      <li>Ipufen (TW);</li>\n      <li>Irfen (AE, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Junifen (ES);</li>\n      <li>Liptan (AE, BH, CY, EG, IL, IQ, IR, JO, JP, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Medicol (PH);</li>\n      <li>Medicol Advance (PH);</li>\n      <li>Mensoton (DE);</li>\n      <li>Mofen (ID);</li>\n      <li>Moris (ID);</li>\n      <li>Moris Forte (ID);</li>\n      <li>Motrin (AE, BH, CO, CR, CY, DO, EG, GT, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, QA, SA, SV, SY, YE);</li>\n      <li>Mutrim (PH);</li>\n      <li>Neoprofen (BM);</li>\n      <li>Neutropain (HK);</li>\n      <li>Nobafon (TW);</li>\n      <li>Noritis (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Novogent (DE);</li>\n      <li>Nureflex (AT);</li>\n      <li>Nurofen (AT, AU, BE, BF, BG, BJ, CI, CY, CZ, DK, ES, ET, FR, GB, GH, GM, GN, HR, HU, IE, IS, KE, LR, LT, LU, LV, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, SC, SD, SE, SG, SI, SK, SL, SN, TN, TR, TZ, UG, VN, ZM, ZW);</li>\n      <li>Nurofen for Children (SG, TH);</li>\n      <li>Nurofen Gel (IL, NZ);</li>\n      <li>Nurofen Pro san sucre (FR);</li>\n      <li>Nuroffen (MT);</li>\n      <li>Nurosan (UA);</li>\n      <li>Optifen (CH);</li>\n      <li>Opturem (DE);</li>\n      <li>Ostarin (ID);</li>\n      <li>P-Fen (TH);</li>\n      <li>Panafen (NZ);</li>\n      <li>Pedea (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, KR, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Peflam (BD);</li>\n      <li>Perfen (TW);</li>\n      <li>Perofen (BB, BM, BS, BZ, GY, JM, SG, SR, TT);</li>\n      <li>Profen (BD, HK);</li>\n      <li>Profinal (AE, BH, KW, LB, MY, QA, SA);</li>\n      <li>Proris (ID);</li>\n      <li>Prosinal (ID);</li>\n      <li>Provon (PE);</li>\n      <li>Quadrax (MX);</li>\n      <li>Rafen (AU);</li>\n      <li>Ranofen (ZA);</li>\n      <li>RatioDolor (AT);</li>\n      <li>Remofen (AE, BH, JO, QA);</li>\n      <li>Rhelafen (ID);</li>\n      <li>Rhelafen Forte (ID);</li>\n      <li>Rheumanox (TH);</li>\n      <li>Rupan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ruprofen (TH);</li>\n      <li>Sapofen (AE, BH, JO, KW, QA, SA);</li>\n      <li>Spedifen (CN, FR);</li>\n      <li>Speedifen (TH);</li>\n      <li>Spifen (FR);</li>\n      <li>Syntofene (FR);</li>\n      <li>Tabalon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tabalon 400 (MX);</li>\n      <li>Tarein (TW);</li>\n      <li>Taskine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Tefin (IE);</li>\n      <li>Tenvalin (EC);</li>\n      <li>Thomaprodol (AT);</li>\n      <li>Ufen (LK);</li>\n      <li>Upfen (FR);</li>\n      <li>Uprofen (TW);</li>\n      <li>Urem (DE);</li>\n      <li>Vantril (PY);</li>\n      <li>Xfen Flashtab (PH);</li>\n      <li>Zofen (MY);</li>\n      <li>Zorafen (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adler Y, Charron P, Imazio M, et al; European Society of Cardiology (ESC). 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J</i>. 2015;36(42):2921-2964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26320112/pubmed\" target=\"_blank\" id=\"26320112\">26320112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advil (ibuprofen) [prescribing information]. Madison, NJ: Pfizer Inc.; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society (APS). Principles of Analgesic Use. 7th ed. Chicago, IL: American Pain Society; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amundsen S, Nordeng H, Nezvalov&aacute;-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. <i>Nat Rev Neurol</i>. 2015;11(4):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25776823/pubmed\" target=\"_blank\" id=\"25776823\">25776823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. <i>Acta Paediatr</i>. 1997;86(3):289-293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9099319/pubmed\" target=\"_blank\" id=\"9099319\">9099319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranda JV, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. <i>Semin Perinatol</i>. 2006;30(3):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16813969/pubmed\" target=\"_blank\" id=\"16813969\">16813969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:105.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker DE. Pain management: Part 1: Managing acute and postoperative dental pain. <i>Anesth Prog</i>. 2010;57(2):67-78; quiz 79-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/20553137/pubmed\" target=\"_blank\" id=\"20553137\">20553137</a>]</span><span class=\"doi\">10.2344/0003-3006-57.2.67</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde C, Ablin A, Glazer J, et al. American Academy of Pediatrics report of the subcommittee on disease-related pain in childhood cancer. <i>Pediatrics</i>. 1990;86(5, pt 2):818-825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2216644/pubmed\" target=\"_blank\" id=\"2216644\">2216644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24663106/pubmed\" target=\"_blank\" id=\"24663106\">24663106</a>]</span><span class=\"doi\">10.1097/BOR.0000000000000054</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2008;52(18):1502-1517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23558845/pubmed\" target=\"_blank\" id=\"23558845\">23558845</a>]</span><span class=\"doi\">10.1213/ANE.0b013e31828a4b54</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. <i>Am Fam Physician</i>. 2013;87(11):766-772.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23939498/pubmed\" target=\"_blank\" id=\"23939498\">23939498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo; <i>N Engl J Med</i>, 1991, 324(24):1716-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2034249/pubmed\" target=\"_blank\" id=\"2034249\">2034249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldolor (ibuprofen) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldolor (ibuprofen) [product monograph]. Toronto, Ontario, Canada: Alveda Pharmaceuticals Inc; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capparelli EV. Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine. <i>J Pediatr Pharmacol Ther</i>. 2007;12(3):158-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23055851/pubmed\" target=\"_blank\" id=\"23055851\">23055851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo; <i>J Am Coll Cardiol</i>, 2005, 45(8):1295-1301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15837265/pubmed\" target=\"_blank\" id=\"15837265\">15837265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo; <i>N Engl J Med</i>, 2001, 345(25):1809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11752357/pubmed\" target=\"_blank\" id=\"11752357\">11752357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo; <i>Hypertension</i>, 2000, 36(3):461-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10988282/pubmed\" target=\"_blank\" id=\"10988282\">10988282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cryer B, Verlin RG, Cooper SA, et al. &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study Of Ibuprofen Effects On Thromboxane B2 Concentrations In Aspirin-Treated Healthy Adult Volunteers,&rdquo; <i>Clin Ther</i>, 2005, 27 (2):185-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15811481/pubmed\" target=\"_blank\" id=\"15811481\">15811481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies NM, &ldquo;Clinical Pharmacokinetics of Ibuprofen. The First 30 Years,&rdquo; <i>Clin Pharmacokinet</i>, 1998, 34(2):101-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9515184/pubmed\" target=\"_blank\" id=\"9515184\">9515184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral ibuprofen for acute postoperative pain in adults. <i>Cochrane Database Syst Rev</i>. 2009;(3):CD001548.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19588326/pubmed\" target=\"_blank\" id=\"19588326\">19588326</a>]</span><span class=\"doi\">10.1002/14651858.CD001548.pub2</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dionne RA and Berthold CW, &ldquo;Therapeutic Uses of Nonsteroidal Anti-inflammatory Drugs in Dentistry,&rdquo; <i>Crit Rev Oral Biol Med</i>, 2001, 12(4):315-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11603504 /pubmed\" target=\"_blank\" id=\"11603504 \">11603504 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dionne R, &ldquo;Additive Analgesia Without Opioid Side Effects,&rdquo; <i>Compend Contin Educ Dent</i>, 2000, 21(7):572-4, 576-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11199661 /pubmed\" target=\"_blank\" id=\"11199661 \">11199661 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dionne R, &ldquo;Relative Efficacy of Selective COX-2 Inhibitors Compared With Over-The-Counter Ibuprofen,&rdquo; <i>Int J Clin Pract Suppl</i>, 2003, (135):18-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12723742 /pubmed\" target=\"_blank\" id=\"12723742 \">12723742 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyle G, Jayawardena S, Ashraf E, et al, &ldquo;Efficacy and Tolerability of Nonprescription Ibuprofen Versus Celecoxib for Dental Pain,&rdquo; <i>J Clin Pharmacol</i>, 2002, 42(8):912-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12162474 /pubmed\" target=\"_blank\" id=\"12162474 \">12162474 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannini EH, Brewer EJ, Miller ML, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. <i>J Pediatr</i>. 1990;117(4):645-652.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2213396/pubmed\" target=\"_blank\" id=\"2213396\">2213396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregoire N, Gualano V, Geneteau A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. <i>J Clin Pharmacol</i>. 2004;44(10):1114-1124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15342612/pubmed\" target=\"_blank\" id=\"15342612\">15342612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo; <i>JAMA</i>, 1990, 264(4):471-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2366280/pubmed\" target=\"_blank\" id=\"2366280\">2366280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo; <i>Arch Intern Med</i>, 1998, 158(10):1108-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9605782/pubmed\" target=\"_blank\" id=\"9605782\">9605782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hersh EV, Levin LM, Cooper SA, et al, &ldquo;Ibuprofen Liquigel for Oral Surgery Pain,&rdquo; <i>Clin Ther</i>, 2000, 22(11):1306-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11117655 /pubmed\" target=\"_blank\" id=\"11117655 \">11117655 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo; <i>Arch Intern Med</i>, 1991, 151(7):1309-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2064481/pubmed\" target=\"_blank\" id=\"2064481\">2064481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ibuprofen [prescribing information]. Glasgow, KY: Amneal Pharmaceuticals; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ibuprofen tablet [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. <i>Circulation</i>. 2005;112(13):2012-2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/16186437/pubmed\" target=\"_blank\" id=\"16186437\">16186437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. <i>N Engl J Med</i>. 2013;369(16):1522-1528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23992557/pubmed\" target=\"_blank\" id=\"23992557\">23992557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Brucato A, Trinchero R, et al, &ldquo;Individualized Therapy for Pericarditis,&rdquo; <i>Expert Rev Cardiovasc Ther</i>, 2009, 7(8):965-975.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/19673674/pubmed\" target=\"_blank\" id=\"19673674\">19673674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman RE and Nelson MV, &ldquo;Effect of Age on Ibuprofen Pharmacokinetics and Antipyretic Response,&rdquo; <i>J Pediatr</i>, 1992, 121(6):969-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/1447669/pubmed\" target=\"_blank\" id=\"1447669\">1447669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lesko SM and Mitchell AA, &ldquo;An Assessment of the Safety of Pediatric Ibuprofen. A Practitioner-Based Randomized Clinical Trial,&rdquo; <i>JAMA</i>, 1995, 273(12):929-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7884951/pubmed\" target=\"_blank\" id=\"7884951\">7884951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. <i>Paediatr Drugs</i>. 2001;3(11):817-858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11735667/pubmed\" target=\"_blank\" id=\"11735667\">11735667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24927294/pubmed\" target=\"_blank\" id=\"24927294\">24927294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maisch B, Seferovi&#263; PM, Risti&#263; AD, et al, &ldquo;Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary; The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology,&rdquo; <i>Eur Heart J</i>, 2004, 25(7):587-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15120056/pubmed\" target=\"_blank\" id=\"15120056\">15120056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchei E, Pellegrini M, Pichini S, et al, &ldquo;Are False-Positive Phencyclidine Immunoassay Instant-View Multi-Test Results Caused by Overdose Concentrations of Ibuprofen, Metamizol, and Dextromethorphan?&rdquo; <i>Ther Drug Monit</i>, 2007, 29(5):671-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17898664/pubmed\" target=\"_blank\" id=\"17898664\">17898664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidalanti-inflammatory drugs for dysmenorrhoea. <i>Cochrane Database Syst Rev</i>. 2010;(1):CD001751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/20091521/pubmed\" target=\"_blank\" id=\"20091521\">20091521</a>]</span><span class=\"doi\">10.1002/14651858.CD001751.pub2</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of analgesia. <i>Int J Clin Pract Suppl</i>. 2013;(178):3-8. doi: 10.1111/ijcp.12053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23163542/pubmed\" target=\"_blank\" id=\"23163542\">23163542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midol liquid gels (ibuprofen) [prescribing information]. Morristown, NJ: Bayer HealthCare LLC; received May 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23163542/pubmed\" target=\"_blank\" id=\"23163542\">23163542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motrin (ibuprofen) [prescribing information]. Fort Washington, PA: Johnson &amp; Johnson Consumer Inc.; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motrin IB (ibuprofen) [prescribing information]. Fort Washington, PA: Johnson &amp; Johnson Consumer Inc.; received March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neoprofen (ibuprofen) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nguyen AM, Graham DY, Gage T, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug Use in Dentistry: Gastrointestinal Implications,&rdquo; <i>Gen Dent</i>, 1999, 47(6):590-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10687453 /pubmed\" target=\"_blank\" id=\"10687453 \">10687453 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novo-Profen (ibuprofen) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olson NZ, Otero AM, Marrero I, et al, &ldquo;Onset of Analgesia for Liquigel Ibuprofen 400 mg, Acetaminophen 1000 mg, Ketoprofen 25 mg, and Placebo in the Treatment of Postoperative Dental Pain,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41(11):1238-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11697757 /pubmed\" target=\"_blank\" id=\"11697757 \">11697757 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo; <i>Arch Intern Med</i>, 2000, 160(6):777-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10737277/pubmed\" target=\"_blank\" id=\"10737277\">10737277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearlman B, Boyatzis S, Daly C, et al, &ldquo;The Analgesic Efficacy of Ibuprofen in Periodontal Surgery: A Multicentre Study,&rdquo; <i>Aust Dent J</i>, 1997, 42(5):328-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9409050 /pubmed\" target=\"_blank\" id=\"9409050 \">9409050 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pope JE, Anderson JJ, and Felson DT, &quot;A Meta-analysis of the Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure,&quot; <i>Arch Intern Med</i>, 1993, 153(4):477-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/8435027/pubmed\" target=\"_blank\" id=\"8435027\">8435027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigourd V, de Villepin B, Amirouche A, et al. Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 &quot;Antalait&quot; study. <i>Ther Drug Monit</i>. 2014;36(5):590-596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24695355 /pubmed\" target=\"_blank\" id=\"24695355 \">24695355 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD000396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/18253976/pubmed\" target=\"_blank\" id=\"18253976\">18253976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saavedra Salinas M&Aacute;, Barrera Cruz A, Cabral Casta&ntilde;eda AR, et al. Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. <i>Reumatol Clin</i>. 2015;11(5):305-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/25683368/pubmed\" target=\"_blank\" id=\"25683368\">25683368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. <i>Curr Opin Rheumatol</i>. 2014;26(3):354-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/24614280 /pubmed\" target=\"_blank\" id=\"24614280 \">24614280 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuijt MP, Huntjens-Fleuren HW, de Metz M, et al, &quot;The Interaction of Ibuprofen and Diclofenac With Aspirin in Healthy Volunteers,&quot; <i>Br J Pharmacol</i>, 2009, 157(6):931-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/1946698/pubmed\" target=\"_blank\" id=\"1946698\">1946698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott CS, Retsch-Bogart GZ, Kustra RP, et al. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. <i>J Pediatr</i>. 1999;134(1):58-63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinhubl SR, &ldquo;The Use of Anti-Inflammatory Analgesics in the Patient With Cardiovascular Disease: What a Pain,&rdquo; <i>J Am Coll Cardiol</i>, 2005, 45(8):1302-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15837266/pubmed\" target=\"_blank\" id=\"15837266\">15837266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sullivan JE, Farrar HC; Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. <i>Pediatrics</i>. 2011;127(3):580-587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/21357332/pubmed\" target=\"_blank\" id=\"21357332\">21357332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B, &ldquo;The Use of Ibuprofen in Neonates in the Treatment of Patent Ductus Arteriosus,&rdquo; <i>Int J Clin Pract Suppl</i>, 2003, (135):23-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/12723743/pubmed\" target=\"_blank\" id=\"12723743\">12723743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B, Smets K, Lecoutere D, et al, &ldquo;A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus,&rdquo; <i>N Engl J Med</i>, 2000, 343(10):674-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/10974130/pubmed\" target=\"_blank\" id=\"10974130\">10974130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Overmeire B, Touw D, Schepens PJ, et al, &ldquo;Ibuprofen Pharmacokinetics in Preterm Infants With Patent Ductus Arteriosus,&rdquo; <i>Clin Pharmacol Ther</i>, 2001, 70(4):336-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/11673749/pubmed\" target=\"_blank\" id=\"11673749\">11673749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1990, 19(1):44-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/2199127/pubmed\" target=\"_blank\" id=\"2199127\">2199127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walter K and Dilger C, &quot;Ibuprofen in Human Milk,&quot; <i>Br J Clin Pharmacol</i>. 1997; 44(2):211-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/9278216/pubmed\" target=\"_blank\" id=\"9278216\">9278216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Update on Nonprescription Pain Relievers for Dental Pain,&rdquo; <i>Gen Dent</i>, 2004, 52(2):94-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/15101300 /pubmed\" target=\"_blank\" id=\"15101300 \">15101300 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ibuprofen-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8547 Version 309.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708913\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181456\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181457\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181507\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181461\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F181483\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181462\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6784600\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F181463\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181416\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23884416\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874617\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181435\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181434\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474800\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181516\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181423\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181438\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181420\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F181500\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181425\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F181452\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7684272\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F181441\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F181442\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181428\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F181431\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181419\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181437\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181440\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181443\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8547|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ibuprofen-patient-drug-information\" class=\"drug drug_patient\">Ibuprofen: Patient drug information</a></li><li><a href=\"topic.htm?path=ibuprofen-pediatric-drug-information\" class=\"drug drug_pediatric\">Ibuprofen: Pediatric drug information</a></li></ul></div></div>","javascript":null}